The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -19.31 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 21.96 — flag raised, worth a closer lookWatch
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Verrica Pharmaceuticals Inc. reports it. History and quarterly detail are in the app.
- License and collaboration revenue$20.3M
- Product revenue, net$15.3M
- License and Collaboration Revenue, Commercial Supply and Development$2.3M
Leadership changes
From Verrica Pharmaceuticals Inc.'s own filings, the day they're filed.
- Charles Frantzreb · director · appointmenteff. 2025-12-26
- Christopher G. Hayes · Chief Legal Officer · departureeff. 2025-04-30
- Hayes Resignation · Chief Compliance Officer · departureeff. 2025-04-30
Latest filings
- 8-K · Company announcement2026-06-09
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-12
- DEF 14A · Annual proxy (pay & governance)2026-04-20
- 10-K · Annual report2026-03-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Verrica Pharmaceuticals Inc., every answer cited🔒
- The Intelligence Brief — added when Verrica Pharmaceuticals Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.